Review article: Liver transplantation for hepatocellular carcinoma - A critical appraisal of the current worldwide listing criteria

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 8, 2014, Pages 893-902

  Menon, K V ^a   Hakeem, A R ^b   Heaton, N D ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER THERAPY; DISEASE MARKER; EVIDENCE BASED PRACTICE; GOLD STANDARD; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOCOREGIONAL THERAPY; MEDICAL LITERATURE; PATIENT CODING; PATIENT IDENTIFICATION; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL PREDICTION; SURVIVAL RATE; UNITED KINGDOM; BLOOD; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PATHOLOGY;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84907897114     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12922     Document Type: Review

References (92)

1. Gonzalez SA, Keeffe EB,. Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy. Front Biosci 2011; 16: 225-50.
2. Turner J, Bansi L, Gilson R, et al,. The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK-trends in HCV testing and the impact of HCV on HIV treatment outcomes. UK Collaborative HIV Cohort (UK CHIC) Study. J Viral Hepat 2010; 17: 569-77.
3. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD,. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-8, Review.
4. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME,. The burden of hepatitis C in England. J Viral Hepat. 2007; 14: 570-6.
5. Salhab M, Canelo R,. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther 2011; 7: 463-75.
6. Feng X, Pai M, Mizandari M, et al,. Towards the optimization of management of hepatocellular carcinoma. Front Med 2011; 5: 271-6.
7. Wong R, Frenette C,. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2011; 7: 16-24.
8. Khorsandi SE, Heaton N,. Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg. 2012; 2012: 154056 (8 pages).
9. Maggs JR, Suddle AR, Aluvihare V, Heneghan MA,. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35: 1113-34.
10. Bartlett A, Heaton N,. Hepatocellular carcinoma: Defining the place of surgery in the era of organ shortage. World J Gastroenterol 2008; 14: 4445-53.
11. Ringe B, Pichlmayr R, Wittekind C, Tusch G,. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15: 270-85.
12. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A,. Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg 1993; 218: 145-51.
13. Mazzaferro V, Regalia E, Doci R, et al,. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
14. Sutcliffe R, Maguire D, Portmann B, Rela M, Heaton N,. Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg 2006; 93: 11-8.
15. Lai Q, Avolio AW, Manzia TM, et al,. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant 2012; 26: E125-31.
16. Clavien PA, Lesurtel M, Bossuyt PM, et al,. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-22.
17. Bismuth H, Majno PE, Adam R,. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19: 311-22.
18. Ravaioli M, Ercolani G, Cescon M, et al,. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004; 10: 1195-202.
19. Llovet JM, Fuster J, Bruix J,. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
20. Shetty K, Timmins K, Brensinger C, et al,. Transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911-8.
21. Llovet JM,. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-35.
22. Yao FY, Ferrell L, Bass NM, et al,. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.
23. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NR, Roberts JP,. Liver transplantation for hepatocellular carcinoma: validation of the UCSF expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-96.
24. Herrero JI, Sangro B, Quiroga J, et al,. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001; 7: 631-6.
25. Roayaie S, Frischer JS, Emre SH, et al,. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinoma larger than 5 centimeters. Ann Surg 2002; 235: 533-9.
26. Kneteman NM, Oberholzer J, Al Saghier M, et al,. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplant 2004; 10: 1301-11.
27. Mazzaferro V, Llovet JM, Miceli R, et al,. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Metroticket Investigator Study Group. Lancet Oncol 2009; 10: 35-43.
28. Guiteau JJ, Cotton RT, Washburn WK, et al,. An early regional experience with expansion of Milan Criteria for liver transplant recipients. Am J Transplant 2010; 10: 2092-8.
29. Yao FY,. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008; 8: 1982-9.
30. Duffy JP, Vardanian A, Benjamin E, et al,. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-11.
31. Leung JY, Zhu AX, Gordon FD, et al,. Liver transplantation for early- stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl 2004; 10: 1343-54.
32. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al,. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006; 12: 1761-9.
33. Schwartz M,. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1): S268-76.
34. NHS Blood and Transplant Liver Advisory Group. Protocols and guidelines for adults undergoing deceased donor liver transplantation in the UK (September 2009). Accessed 18 November 2013.
35. Figueras J, Jaurrieta E, Valls C, et al,. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25: 1485-9.
36. Figueras J, Jaurrieta E, Valls C, et al,. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000; 190: 580-7.
37. Todo S, Furukawa H,. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Japanese Study Group on Organ Transplantation. Ann Surg 2004; 240: 451-9.
38. Roayaie S, Schwartz JD, Sung MW, et al,. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-40.
39. Löhe F, Angele MK, Gerbes AL, Löhrs U, Jauch KW, Schauer RJ,. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2005; 31: 994-9.
40. Löhe F, Angele MK, Rentsch M, et al,. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant 2007; 21: 696-701.
41. Yang SH, Suh KS, Lee HW, et al,. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007; 141: 598-609.
42. Obed A, Beham A, Püllmann K, Becker H, Schlitt HJ, Lorf T,. Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol 2007; 13: 761-7.
43. Klintmalm GB,. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228: 479-90.
44. Iwatsuki S, Dvorchik I, Marsh JW, et al,. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 2000; 191: 389-94.
45. Figueras J, Ibañez L, Ramos E, et al,. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl 2001; 7: 877-83.
46. Taketomi A, Sanefuji K, Soejima Y, et al,. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009; 87: 531-7.
47. Tamura S, Kato T, Berho M, et al,. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136: 25-30.
48. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ,. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233: 652-9.
49. Wu L, Xu X, Shen J, et al,. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol 2007; 96: 62-8.
50. Kondili LA, Lala A, Gunson B, et al,. Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. Eur J Surg Oncol 2007; 33: 868-73.
51. Otto G, Herber S, Heise M, et al,. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-7.
52. Fan J, Yang GS, Fu ZR, et al,. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 2009; 135: 1403-12.
53. Halazun KJ, Hardy MA, Rana AA, et al,. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141-51.
54. Söderdahl G, Bäckman L, Isoniemi H, et al,. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006; 19: 288-94.
55. Jang JW, You CR, Kim CW, et al,. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010; 31: 415-23.
56. Li J, Yan LN, Yang J, et al,. Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. World J Gastroenterol 2009; 15: 4170-6.
57. Toso C, Trotter J, Wei A, et al,. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14: 1107-15.
58. Marelli L, Grasso A, Pleguezuelo M, et al,. Tumour size and differentiation in predicting recurrence of hepatocellular carcinoma after liver transplantation: external validation of a new prognostic score. Ann Surg Oncol 2008; 15: 3503-11.
59. Morisco F, Stigliano R, Godfrey A, et al,. Efficacy of loco-regional ablation therapy of HCC in a population of liver transplanted patients. Dig Dis Sci 2008; 53: 1131-7.
60. Grasso A, Stigliano R, Morisco F, et al,. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation 2006; 81: 1532-41.
61. Bhattacharjya S, Bhattacharjya T, Quaglia A, et al,. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators. Dig Surg 2004; 21: 152-9; discussion 159-60.
62. Young RS, Aldiwani M, Hakeem AR, et al,. Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation? HPB (Oxford). 2013; 15: 418-27.
63. Unitt E, Marshall A, Gelson W, et al,. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45: 246-53.
64. Park SJ, Freise CE, Hirose R, et al,. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma. Clin Transplant 2012; 26: E359-64.
65. Yao FY, Bass NM, Nikolai B, et al,. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8: 873-83.
66. United Network for Organ Sharing (UNOS). Policy 3.6 organ distribution: allocation of livers. Revised 14th December 2006. http://www.unos.org/policiesandbylaws/policies.asp?resources=true. Accessed 18 November 2013.
67. Sharma P, Balan V, Hernandez JL, et al,. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004; 10: 36-41.
68. Levi DM, Tzakis AG, Martin P, et al,. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg 2010; 210: 727-34.
69. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R,.
70. Sharma P, Harper AM, Hernandez JL, et al,. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant 2006; 6: 1957-62.
71. Neuberger J, Gimson A, Davies M, et al,. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 2008; 57: 252-7.
72. Llovet JM, Fuster J, Bruix J,. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
73. Yao FY, Bass NM, Nikolai B, et al,. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9: 684-92.
74. Freeman RB, Edwards EB, Harper AM,. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006; 6: 1416-21.
75. Washburn K, Edwards E, Harper A, Freeman R,. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010; 10: 1643-8.
76. UK Transplant report 2009-2010. http://www.nhsbt.nhs.uk/downloads/pdfs/temp/report.pdf. Accessed 18 November 2013.
77. Bharat A, Brown DB, Crippin JS, et al,. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg 2006; 203: 411-20.
78. Mazzaferro V, Battiston C, Perrone S, et al,. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation. A prospective study. Ann Surg 2004; 240: 900-9.
79. Graziadei IW, Sandmueller H, Waldenberger P, et al,. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9: 557-63.
80. Tsochatzis E, Garcovich M, Marelli L, et al,. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int 2013; 33: 944-9.
81. Merani S, Majno P, Kneteman NM, et al,. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814-9.
82. Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR,. Systematic review: the prognostic role of alpha-fetoprotein following liver transplant forhepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35: 987-99.
83. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-8.
84. Han K, Tzimas GN, Barkun JS, et al,. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007; 21: 39-45.
85. Vibert E, Azoulay D, Hoti E, et al,. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-37.
86. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NR, Roberts JP,. Liver transplantation for hepatocellular carcinoma: validation of the UCSF expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-96.
87. Llovet JM, Schwartz M, Mazzoferro V,. Resection and liver transplantation for hepatocellular carcinoma. Semin Liv Dis 2005; 25: 181-200.
88. Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB,. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007; 13: 391-9.
89. Massie AB, Caffo B, Gentry SE, et al,. MELD Exceptions and Rates of Waiting List Outcomes. Am J Transplant 2011; 11: 2362-71.
90. Volk ML, Vijan S, Marrero JA,. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008; 8: 839-46.
91. Cucchetti A, Cescon M, Ercolani G, et al,. Comparison between observed survival after resection of transplantable hepatocellular carcinoma and predicted survival after listing through a Markov model simulation. Transpl Int 2011; 24: 787-96.
92. Cillo U, Vitale A, Grigoletto F, et al,. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transplant 2007; 7: 972-81.